Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Sofia Pimenta
Based on 4 articles published since 2008
||||

Between 2008 and 2019, S. Pimenta wrote the following 4 articles about Spinal Diseases.
 
+ Citations + Abstracts
1 Guideline Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis - 2016 update. 2017

Machado, Pedro / Cerqueira, Marcos / Ávila-Ribeiro, Pedro / Aguiar, Renata / Bernardo, Alexandra / Sepriano, Alexandre / Águeda, Ana / Cordeiro, Ana / Raposo, Ana / Rodrigues, Ana M / Barcelos, Anabela / Malcata, Armando / Lopes, Carina / Vaz, Cláudia C / Nour, Dolores / Godinho, Fátima / Alvarenga, Fernando / Pimentel-Santos, Fernando / Canhão, Helena / Santos, Helena / Cunha, Inês / Neves, Joana Sousa / Fonseca, João Eurico / Gomes, João Lagoas / Tavares-Costa, José / Costa, Lúcia / Cunha-Miranda, Luís / Maurício, Luís / Cruz, Margarida / Afonso, Maria Carmo / Santos, Maria José / Bernardes, Miguel / Valente, Paula / Figueira, Ricardo / Pimenta, Sofia / Ramiro, Sofia / Pedrosa, Teresa / Costa, Tiago Afonso / Vieira-Sousa, Elsa. ·University College London, London, UK. · Rheumatology Department, Unidade Local de Saúde do Alto Minho, Hospital Conde de Bertiandos, Ponte de Lima, Portugal. · Rheumatology and Metabolic Bone Diseases Department, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisboa, Portugal. · Rheumatology Department, Centro Hospitalar do Baixo Vouga, Hospital de Aveiro, Aveiro, Portugal. · Rheumatology Department, Centro Hospitalar de S. João, Porto, Portugal. · NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal. · Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal. · Rheumatology Department, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal. · CEDOC, EpiDoC Unit, NOVA Medical School and National School of Public Health, Universidade Nova de Lisboa, Lisboa, Portugal. · Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. · CEDOC, EpiDoC Unit, NOVA Medical School and National School of Public Health, Universidade Nova de Lisboa; Rheumatology Department, Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz, Lisboa, Portugal. · Rheumatology Department, Unidade Local de Saúde da Guarda, Guarda, Portugal. · Clínica Intregare Terapêutica - Fortaleza: Clínica da Família, Fortaleza, Brasil. · Consultório Privado de Reumatologia, Portugal. · Instituto Português de Reumatologia, Lisboa, Portugal. · Rheumatology and Metabolic Bone Diseases Department, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, P. · Rheumatology Department, Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz, Lisboa, Portugal. · Centro Hospitalar de Entre o Douro e Vouga, Hospital de São Sebastião, Santa Maria da Feira, Portugal. · Centro Hospitalar do Funchal, Funchal, Madeira, Portugal. · NOVA Medical School, Universidade Nova de Lisboa; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. ·Acta Reumatol Port · Pubmed #28894079.

ABSTRACT: OBJECTIVE: To update the recommendations for the treatment of axial spondyloarthritis (axSpA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. At a national meeting, the 7 recommendations included in this document were discussed and updated. A draft of the full text of the recommendations was then circulated and suggestions were incorporated. A final version was again circulated before publication and the level of agreement among Portuguese Rheumatologists was anonymously assessed using an online survey. RESULTS: A consensus was achieved regarding the initiation, assessment of response and switching of biological therapies in patients with axSpA. In total, seven recommendations were produced. The first recommendation is a general statement indicating that biological therapy is not a first-line drug treatment option and should only be used after conventional treatment has failed. The second recommendation is also a general statement about the broad concept of axSpA adopted by these recommendations that includes both non-radiographic and radiographic axSpA. Recommendations 3 to 7 deal with the definition of active disease (including the recommended threshold of 2.1 for the Ankylosing Spondylitis Disease Activity Score [ASDAS] or the threshold of 4 [0-10 scale] for the Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), conventional treatment failure (nonsteroidal anti-inflammatory drugs being the first-line drug treatment), assessment of response to treatment (based on an ASDAS improvement  of at least 1.1 units or a BASDAI improvement of at least 2 units [0-10 scale] or at least 50%), and strategy in the presence of an inadequate response (where switching is recommended) or in the presence of long-term remission (where a process of biological therapy optimization can be considered, either a gradual increase in the interval between doses or a decrease of each dose of the biological therapy). CONCLUSION: These recommendations may be used for guidance in deciding which patients with axSpA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

2 Guideline PORTUGUESE RECOMMENDATIONS FOR THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH PSORIATIC ARTHRITIS--2015 UPDATE. 2015

Vieira-Sousa, Elsa / Machado, Pedro M / Costa, José / Ribeiro, Ana / Aguiar, Renata / Cerqueira, Marcos / Neto, Adriano / Bernardo, Alexandra / Cordeiro, Ana / Duarte, Cátia / Vinagre, Filipe / Canhão, Helena / Santos, Helena / Neves, Joana Sousa / Cunha-Miranda, Luís / Silva, Margarida / Santos, Maria José / Bernardes, Miguel / Bogas, Mónica / Abreu, Pedro / Viana-Queiroz, Mário / Barros, Rita / Falcão, Sandra / Pimenta, Sofia / Teixeira, Vitor / Fonseca, João Eurico / Barcelos, Anabela / Anonymous2490850. · ·Acta Reumatol Port · Pubmed #26610694.

ABSTRACT: OBJECTIVE: To update recommendations for the treatment of psoriatic arthritis with biological therapies, endorsed by the Portuguese Society of Rheumatology (SPR). METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. At a national meeting the 16 recommendations included in this document were discussed and updated. The level of agreement among Portuguese Rheumatologists was assessed using an online survey. A draft of the full text of the recommendations was then circulated and suggestions were incorporated. A final version was again circulated before publication. RESULTS: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with psoriatic arthritis (PsA). Specific recommendations were developed for several disease domains: peripheral arthritis, axial disease, enthesitis and dactylitis. CONCLUSION: These recommendations may be used for guidance in deciding which patients with PsA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

3 Review Off-label Use of Tocilizumab in Psoriatic Arthritis: Case Series and Review of the Literature. 2016

Madureira, P / Pimenta, S S / Bernardo, A / Brito, J S / Bernardes, M / Costa, L. · ·Acta Reumatol Port · Pubmed #27155213.

ABSTRACT: OBJECTIVE: To evaluate the efficacy of tocilizumab (TCZ) on three patients with psoriatic arthritis (PsA) and review the literature for other cases of PsA treated with TCZ. CLINICAL CASES: The first patient started TCZ treatment after the failure of adalimumab (ADA), and etanercept (ETA) (Disease Activity Score, DAS28: 6.66) to treat PsA. After 12 months, her DAS28 decreased to 3.26, and at present (24 months), she has achieved disease remission. The second patient started TCZ treatment after the failure of ADA. After 12 months, the DAS28 decreased from 4.90 to 3.99. After 48 months of treatment, the patient had a DAS28 of 3.76. The third case was treated with TCZ after the failure of both infliximab and rituximab therapy. After 12 months, the DAS28 dropped from 8.65 to 5.49. At present, after 37 months of treatment, the patient has a DAS28 of 4.67. In the literature, there are six cases of PsA, which have been treated with TCZ: in two of the cases, the patient showed a great improvement. Two cases failed to achieve disease remission, despite a moderate response to the treatment, and the other two cases showed no improvement. CONCLUSION: It can be concluded that TCZ cannot be recommended as an alternative treatment for PsA with predominant peripheral involvement.

4 Article The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy. 2018

Vieira-Sousa, Elsa / Canhão, Helena / Alves, Pedro / Rodrigues, Ana Maria / Teixeira, Filipa / Tavares-Costa, José / Bernardo, Alexandra / Pimenta, Sofia / Pimentel-Santos, Fernando / Gomes, João L / Aguiar, Renata / Videira, Taciana / Pinto, Patrícia / Catita, Cristina / Santos, Helena / Borges, Joana / Sequeira, Graça / Ribeiro, Célia / Teixeira, Lídia / Ávila-Ribeiro, Pedro / Martins, Fernando M / Ribeiro, Ruy M / Fonseca, João Eurico. ·Hospital de Santa Maria, CHLN; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal. · NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal. · Centro Hospitalar de Lisboa Central, Lisboa, Portugal. · Hospital do Santo Espírito da Ilha Terceira, Açores e Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal. · Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal. · Centro Hospitalar São João do Porto, Porto, Portugal. · Centro Hospitalar de Lisboa Ocidental (CHLO), Hospital de Egas Moniz, Lisboa, Portugal. · Centro Hospitalar do Baixo Vouga, Aveiro, Portugal. · Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal. · Centro Hospitalar do Algarve, Faro, Portugal. · Hospital Garcia de Orta, Almada, Portugal. ·Acta Reumatol Port · Pubmed #30091952.

ABSTRACT: The GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 24 weeks. Both clinical (dactylitis severity score and the Leeds dactylitis index) and imaging (high resolution magnetic resonance imaging), among others, were assessed as outcomes. The main objective of GO-DACT is to provide evidence to improve the treatment algorithm and care of psoriatic arthritis patients with active dactylitis. In this manuscript we describe the GO-DACT protocol and general concepts of the methodology of this trial.